Combined pharmaceutical composition and application thereof

Through the combination of CCR2/5 dual receptor antagonist and BTK inhibitor, the existing problems of localized efficacy and toxic side effects of diffuse large B-cell lymphoma were solved, and significant tumor inhibition effect and good safety treatment were achieved. plan.

CN118987211AActive Publication Date: 2024-11-22SHENZHEN LINGFANG BIOTECH CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202410601215.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-22
Filing Date
2024-05-15
Publication Date
2024-11-22
Estimated Expiration
2044-05-15

AI Technical Summary

Technical Problem

The existing methods for treating diffuse large B-cell lymphoma have limited efficacy and have greater toxic and side effects, especially in patients with relapse or refractory treatment, and the existing BTK inhibitors have not been approved in DLBCL, but are clinically Recommended in practice.

Method used

The combination of CCR2/5 dual receptor antagonist and BTK inhibitor was used, and LF0376 was specifically used as the CCR2/5 dual receptor antagonist, combined with Zebutinib or ibrutinib as BTK inhibitor, and used to treat B cells Lymphoma, especially diffuse large B-cell lymphoma.

Benefits of technology

This combination drug significantly inhibited the growth of B-cell lymphoma, had a stronger tumor-inhibiting effect than a single drug, and showed good safety and good tolerance in mouse models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004840625850000071
    Figure BDA0004840625850000071
  • Figure BDA0004840625850000072
    Figure BDA0004840625850000072
  • Figure BDA0004840625850000081
    Figure BDA0004840625850000081
Patent Text Reader

Abstract

The invention relates to the technical field of medicines, in particular to a combined pharmaceutical composition and application thereof. The pharmaceutical composition comprises a CCR2 / 5 double-receptor antagonist and a Bruton's tyrosine kinase inhibitor. The drug combination of the LF0376 and the zebrutinib and the drug combination of the LF0376 and the ibrutinib have an obvious tumor inhibition effect on B cell lymphoma compared with a single drug.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of medical technology, and in particular to a combined pharmaceutical composition and its application. Background Art

[0002] Lymphoma is a common malignant tumor in my country, with an annual incidence of about 75,400 people, an incidence rate of 4.75 / 100,000, a death rate of 40,500, and a mortality rate of 2.64 / 100,000. There are also significant differences between regions and between urban and rural areas. Lymphoma can be divided into Hodgkin's lymphoma and non-Hodgkin's lymphoma, which have complex pathological types, diverse treatment methods, and different prognoses. Therefore, multidisciplinary teams are generally required in the diagnosis and treatment process. Among non-Hodgkin's lymphomas, diffuse large B-cell lymphoma (DLBCL) accounts for about 30% to 40%. Its standard treatment is immunotherapy combined with chemotherapy (R-CHOP). About 50%-60% of patients can be cured by current standard treatment, but 40% to 50% of patients still become refractory or relapse after treatment (about 15% to 25% of patients are primary refractory (progression during or after treatment), about 20% to 30% of patients relapse after complete remission (CR), and 5% of patients are in partial remission (PR). For the above relapsed / refractory patients, Blood stem cell transplantation and CART are the first-choice treatment methods, but due to the high conditions and price of transplantation, the target population is limited, while the remaining treatment methods are mainly chemotherapy, which has limited efficacy and large toxic side effects. In addition, young high-risk or medium-high-risk patients, "double hit" with simultaneous rearrangement of MYC and BCL2, "triple hit" with rearrangement of BCL6, "double expression" with both MYC and BCL2, and non-germinal center B-cell-like subtype lymphoma all indicate a poor prognosis. There is currently no effective treatment measure, and there is an unmet clinical need.

[0003] Both CCR2 and CCR5 are G protein-coupled receptors that can recognize chemokines and have 73% sequence homology. The main ligand of CCR2 is the chemokine CCL2, and it can also recognize CCL7, CCL8, CCL12 and CCL13; CCR5 has a high affinity for multiple chemokines such as CCL3, CCL4, CCL5, CCL3L1, CCL8, CCL11, etc. CCR2 is mainly expressed on monocytes, NK cells and T cells, and these cells can be recruited to the inflammatory site under inflammatory conditions. In most cases, the CCR2-CCL2 axis mainly plays a pro-inflammatory role, but CCR2 expressed on Treg cells plays an anti-inflammatory role. CCR5 is more widely expressed, including T cells, macrophages, granulocytes, DCs, microglia and even epidermal cells.

[0004] In the course of many diseases, such as viral infection and liver fibrosis, which involve inflammatory responses, both CCR2 and CCR5 mediate the migration and infiltration of lymphocytes, monocytes, and macrophages, promoting the occurrence and development of the disease. Studies have shown that CCR2 is more relevant to the migration and infiltration of monocytes and macrophages, while CCR5 has a greater effect on lymphocytes. Therefore, although CCR2 and CCR5 have similarities in function, their emphasis is not the same.

[0005] There are currently no studies demonstrating a specific link between CCR2 / 5 dual receptor antagonists and B-cell lymphoma.

[0006] Bruton tyrosine kinase (BTK) is a key kinase in the BCR signal transduction pathway. BTK is expressed in myeloid cells such as B lymphocytes, basophils, and monocytes. Based on the outstanding efficacy of the first-generation BTK inhibitor Ibrutinib in multiple clinical trials, it has been approved by the FDA for seven indications, including small lymphocytic lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, Waldenstrom's macroglobulinemia, macroglobulinemia, graft-versus-host disease, and marginal zone lymphoma, of which the first three have been approved in China; the second-generation highly selective BTK inhibitor Zanubrutinib is a new anticancer drug independently developed in China, and has also been approved in adult mantle cell lymphoma, Waldenstrom's macroglobulinemia, relapsed / refractory marginal zone lymphoma, and chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Although BTK inhibitors are not approved in DLBCL, they are recommended for this indication by the CSCO guidelines based on clinical practice. Summary of the invention

[0007] In view of the shortcomings of the prior art described above, the purpose of this application is to provide a combined pharmaceutical composition and its application to solve the problems in the prior art. The combination of CCR2 / 5 dual receptor antagonist and BTK inhibitor is used to treat B cell lymphoma, especially diffuse large B cell lymphoma. This study provides a new direction for exploring the combination of the two in the treatment of B cell lymphoma.

[0008] To achieve the above-mentioned purpose and other related purposes, the first aspect of the present application provides the use of a CCR2 / 5 dual receptor antagonist in the preparation of a drug for treating or preventing B-cell lymphoma.

[0009] In any embodiment of the present application, the CCR2 / 5 dual receptor antagonist is selected from a combination of one or more of LF0376, BMS-813160, and Cenicriviroc; preferably, the CCR2 / 5 dual receptor antagonist is selected from LF0376.

[0010] The second aspect of the present application provides a pharmaceutical composition comprising a CCR2 / 5 dual receptor antagonist and a Bruton's tyrosine kinase inhibitor.

[0011] In any embodiment of the present application, the Bruton's tyrosine kinase inhibitor is selected from zanubrutinib, ibrutinib, spebrutinib, acalabrutinib, olmutinib, poseltinib, tirabrutinib, evobrutinib, fenebrutinib, vecabrutinib, ARQ-531, BMS-986195, BMS-986142, CGI-1746, GDC-0834, RN-486, JNJ-642646 81. A combination of one or more of DTRMWXHS-12, CT-1530, AC0058TA, ICP-022, WXFL10230486, SHR1459, PRN-1008, PRN-473, PRN-2246, LOU-064, LOXO-305, ABBV-105, PCI-45292, TAK-020, M-7583, BIIB-068, BMS-935177, CNX-774, TAS-5315, TGH-663, and LFM-A13.

[0012] In any embodiment of the present application, the Bruton's tyrosine kinase inhibitor is selected from zanubrutinib or ibrutinib.

[0013] In any embodiment of the present application, the pharmaceutical composition comprises LF0376 and ibrutinib; preferably, the weight ratio of LF0376 to ibrutinib is 0.5-10:1.

[0014] In any embodiment of the present application, the pharmaceutical composition comprises LF0376 and zanubrutinib; preferably, the weight ratio of LF0376 to zanubrutinib is 0.8-40:1.

[0015] The third aspect of the present application provides the use of the pharmaceutical composition in the preparation of drugs for treating or preventing cancer.

[0016] In any embodiment of the present application, the cancer is selected from one or more combinations of B-cell lymphoma, bladder cancer, blood cancer, bone cancer, brain cancer, breast cancer, central nervous system cancer, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, gallbladder cancer, gastrointestinal cancer, external genital cancer, urogenital tract cancer, head cancer, kidney cancer, laryngeal cancer, liver cancer, lung cancer, muscle tissue cancer, cervical cancer, oral or nasal mucosal cancer, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, spleen cancer, small intestine cancer, large intestine cancer, stomach cancer, testicular cancer and thyroid cancer.

[0017] In any embodiment of the present application, the B cell lymphoma is diffuse large B cell lymphoma.

[0018] The fourth aspect of the present application provides a drug for treating cancer, comprising the CCR2 / 5 dual receptor antagonist in the aforementioned use, or the aforementioned pharmaceutical composition, and pharmaceutically acceptable excipients and / or carriers.

[0019] Compared with the prior art, the beneficial effects of this application are:

[0020] 1. This application discloses for the first time that LF0376 has a significant tumor-suppressing effect on B-cell lymphoma.

[0021] 2. The combination of LF0376 and Zebutinib has a significant tumor inhibitory effect on B-cell lymphoma compared with single drug use.

[0022] 3. The combination of LF0376 and ibrutinib has a significant tumor inhibitory effect on B-cell lymphoma compared with single drug use. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 Shown is the experimental design diagram for the combination of LF0376 and zanubrutinib.

[0024] Figure 2 The figure shows the tumor inhibition curve of the experiment of LF0376 (200 mg) combined with Zanubrutinib in Example 1. Each data point is represented by mean±sem.

[0025] Figure 3 The tumor weight after 27 days of treatment in the experiment of LF0376 (200 mg) combined with Zanubrutinib in Example 1 is shown. Each data point is represented by mean±sem.

[0026] Figure 4 Shown is the percentage (%) of body weight change compared to the baseline of mice during the treatment period of Example 1. Each data point is represented by mean±sem.

[0027] Figure 5 Shown is the experimental design diagram for the combination of LF0376 and ibrutinib.

[0028] Figure 6 The tumor inhibition curve of LF0376 (100 mg) combined with Ibrutinib in Example 1 is shown. Each data point is represented by mean±sem.

[0029] Figure 7The tumor weight after 27 days of treatment in the experiment of LF0376 (100 mg) combined with Ibrutinib in Example 1 is shown. Each data point is represented by mean±sem.

[0030] Figure 8 Shown is the percentage (%) of body weight change compared to the baseline of mice during the treatment period of Example 1. Each data point is represented by mean±sem.

[0031] Fig. 9 Shown is the tumor volume change curve of all experimental groups in Example 2.

[0032] Fig.10 Shown are the tumor volume change curves of the Vehicle group, LF0376 monotherapy group, Ibrutinib monotherapy group and LF0376+Ibrutinib group in Example 2.

[0033] Fig.11 Shown are the tumor volume change curves of the Vehicle group, LF0376 monotherapy group, Zanubrutinib monotherapy group and LF0376+Zanubrutinib group in Example 2.

[0034] Fig.12 Shown is the tumor weight of each experimental group at the end of the experiment in Example 2 (day 28).

[0035] Fig.13 Shown are the tumor weights of the Vehicle group, LF0376 monotherapy group, Ibrutinib monotherapy group, and LF0376+Ibrutinib group at the end of the experiment in Example 2 (Day 28).

[0036] Fig.14 Shown are the tumor weights of the Vehicle group, LF0376 monotherapy group, Zanubrutinib monotherapy group, and LF0376+Zanubrutinib group at the end of the experiment in Example 2 (Day 28).

[0037] Fig.15 Shown is the average RCBW (%) curve of tumor-bearing mice during the treatment with the test drug in Example 2.

[0038] Fig.16 The figure shows the average body weight change curve of tumor-bearing mice during the treatment with the test drug in Example 2.

[0039] Fig.17 The graph shows the changes in tumor volume during the treatment period of each group of mice. Note: The data points represent the mean of the tumor volume of each group, and the error bars represent SEM.

[0040] Fig.18 Shown are graphs showing changes in individual tumor volumes during treatment in each group of mice.

[0041] Fig.19 The tumor weight of each group of PG-D13 mice is shown. Note: Data points represent the tumor weight of mice, the midline represents the mean of the tumor weight of each group, and the error bars represent the SEM.

[0042] Fig. 20 The graph shows the average body weight of each group of mice during the treatment period. Note: Data points represent the mean body weight of each group. Error bars represent SEM.

[0043] Fig.21 The weight changes of mice in each group compared with the baseline during the treatment period. Note: The data points represent the mean of the weight change rate of each group, and the error bars represent SEM. DETAILED DESCRIPTION

[0044] In order to make the invention purpose, technical scheme and beneficial effects of the present application clearer, the present application is further described below in conjunction with the examples. It should be understood that the following examples are only used to explain the present application and are not used to limit the scope of the application. The test methods used in the following examples are conventional methods unless otherwise specified, and people familiar with this technology can easily understand other advantages and effects of the present application from the contents disclosed in this description.

[0045] After extensive exploration and research, the inventor of the present application discovered a combined pharmaceutical composition and its application, and completed the present application on this basis.

[0046] On the one hand, the present application provides the use of a CCR2 / 5 dual receptor antagonist in the preparation of a drug for treating or preventing B-cell lymphoma.

[0047] In the pharmaceutical composition provided in the present application, the CCR2 / 5 dual receptor antagonist is selected from a combination of one or more of LF0376, BMS-813160, and Cenicriviroc. CCR2 / 5 is a cell surface chemokine receptor 2 and 5, a member of the G protein-coupled receptor superfamily, expressed on the surface of a variety of cells, and exerts biological effects by binding to its specific ligand. Preferably, the CCR2 / 5 dual receptor antagonist is selected from LF0376, also known as an azabenzo eight-membered ring compound, and other code names are WXFL40050414 or WXSH0376. In a preferred embodiment of the present application, LF0376 is produced by Shanghai WuXi AppTec New Drug Development Co., Ltd. on behalf of the applicant, with a batch number of ES16578-17-P1, a molecular weight of 739.98, a purity of 97.28%, and is stored at room temperature. This application discloses for the first time the specific connection between CCR2 / 5 dual receptor antagonist (LF0376) and B-cell lymphoma, and the use of LF0376 has a significant tumor-suppressing effect on B-cell lymphoma.

[0048] On the other hand, the present application provides a pharmaceutical composition comprising a CCR2 / 5 dual receptor antagonist and a Bruton's tyrosine kinase inhibitor.

[0049] In some embodiments, the composition of the pharmaceutical composition is a clinically acceptable dose, depending on the species, weight, age and type of tumor to be treated, the condition of the individual case or its severity. A doctor, clinician or veterinarian who has the relevant field of treatment technology can easily determine the effective dose of the pharmaceutical composition required to prevent, treat or inhibit the development of a disorder or disease.

[0050] In the pharmaceutical composition provided in the present application, the Bruton's tyrosine kinase inhibitor is selected from zanubrutinib, ibrutinib, spebrutinib, acalabrutinib, olmutinib, poseltinib, tirabrutinib, evobrutinib, fenebrutinib, vecabrutinib, ARQ-531, BMS-986195, BMS-986142, CGI-1746, GDC-0834, RN-486, JNJ-6426468 1. A combination of one or more of DTRMWXHS-12, CT-1530, AC0058TA, ICP-022, WXFL10230486, SHR1459, PRN-1008, PRN-473, PRN-2246, LOU-064, LOXO-305, ABBV-105, PCI-45292, TAK-020, M-7583, BIIB-068, BMS-935177, CNX-774, TAS-5315, TGH-663, and LFM-A13. Bruton's tyrosine kinase inhibitor (BTK) is an important signaling molecule in the B cell receptor pathway. It is expressed at various developmental stages of B lymphocytes, participates in regulating the proliferation, differentiation, and apoptosis of B cells, and plays an important role in the survival and spread of malignant B cells.

[0051] In the pharmaceutical composition provided in the present application, the Bruton's tyrosine kinase inhibitor is selected from Zanubrutinib or Ibrutinib. Zanubrutinib is a multi-target kinase inhibitor and the first approved BTK small molecule inhibitor. It inhibits the activity of the BTK enzyme by forming a covalent bond with the cysteine ​​in the BTK active site. Ibrutinib belongs to the second generation of BTK inhibitors, which irreversibly inactivates the enzyme by covalently binding to tyrosine kinase. In a preferred embodiment of the present application, Zanubrutinib is produced by MCE and the item number is Lot#79640. Ibrutinib is produced by MCE and the item number is Lot#114225.

[0052] In the pharmaceutical composition provided in the present application, the pharmaceutical composition is LF0376 and ibrutinib, and the weight ratio of the two is 0.5 to 10:1. In a specific embodiment of the present application, the weight ratio of LF0376 and ibrutinib can be, for example, 0.5 to 1:1, 1 to 2.5:1, 2.5 to 5:1, 5 to 8:1, or 8 to 10:1. More specifically, the weight ratio of LF0376 and ibrutinib can be 5:1. In some embodiments, the efficacy of LF0376 and ibrutinib has a synergistic effect in the treatment of B-cell lymphoma.

[0053] In the pharmaceutical composition provided in the present application, the pharmaceutical composition is LF0376 and zanubrutinib, and the weight ratio of the two is 0.8-40:1. In a specific embodiment of the present application, the weight ratio of LF0376 and zanubrutinib can be, for example, 0.8-1:1, 1-5:1, 5-10:1, 10-20:1, 20-30:1, 30-40:1, or 40-50:1. More specifically, the weight ratio of LF0376 and zanubrutinib can be 40:1. In some embodiments, the efficacy of LF0376 and zanubrutinib has a synergistic effect in the treatment of B-cell lymphoma.

[0054] In the pharmaceutical composition provided in the present application, the mode of administration is simultaneous or sequential administration. The therapeutically effective dose of the pharmaceutical composition depends on the species, weight, age and tumor type treated, the condition of the individual case or its severity. Doctors, clinicians or veterinarians who master the treatment techniques in the relevant field can easily determine the use of the aforementioned pharmaceutical composition in the preparation of a drug for treating or preventing cancer by the active ingredients required for preventing, treating or inhibiting the development of disorders or diseases. The term "treatment" used herein includes treatment that slows down, alleviates or relieves at least one symptom in the subject or achieves delayed disease development. For example, treatment can be to reduce one or more symptoms of the disease or completely eliminate the disease, such as cancer. Within the meaning of the present disclosure, the term "treatment" also refers to blocking, delaying the occurrence of the disease (i.e., the stage before the clinical manifestation of the disease) and / or reducing the risk of disease development or deterioration. The term "prevention" used herein includes preventing at least one symptom, which is related to or caused by the prevented state, disease or disorder.

[0055] In the application provided by the present application, the cancer is selected from one or more combinations of B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, slow cell lymphoma, bladder cancer, blood cancer, bone cancer, brain cancer, breast cancer, central nervous system cancer, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, gallbladder cancer, gastrointestinal cancer, external genital cancer, urogenital tract cancer, head cancer, kidney cancer, laryngeal cancer, liver cancer, lung cancer, muscle tissue cancer, cervical cancer, oral or nasal mucosal cancer, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, spleen cancer, small intestine cancer, large intestine cancer, stomach cancer, testicular cancer and thyroid cancer.

[0056] In the application provided by the present application, the B cell lymphoma is diffuse large B cell lymphoma.

[0057] On the other hand, the present application provides a drug for treating cancer, including the CCR2 / 5 dual receptor antagonist in the aforementioned use, or the aforementioned pharmaceutical composition, and pharmaceutically acceptable excipients and / or carriers. The term "pharmaceutically acceptable" as used herein refers to compounds, therapeutic agents (such as antibodies), materials, compositions and / or dosage forms suitable for contacting warm-blooded animals such as mammals or human tissues within a reasonable judgment range, without excessive toxicity, irritation, allergic reactions and other problems or complications, and with a reasonable benefit / benefit ratio. The term "carrier" or "excipient" used herein includes any and all solvents, dispersion media, coating agents, surfactants, antioxidants, preservatives (such as antibacterial agents, antifungal agents), isotonic agents, absorption delay agents, salts, preservatives, drugs, drug stabilizers, adhesives, excipients, disintegrants, lubricants, sweeteners, flavoring agents, dyes, etc., and combinations thereof, and must have sufficiently high purity and very low toxicity to make them suitable for being given to patients to be treated. The carrier can be inert or it can have pharmaceutical benefits itself. Some carriers may be listed in more than one category, e.g., vegetable oils may be used as lubricants in some formulations and as diluents in other formulations. Exemplary pharmaceutical carriers include sugars, starches, cellulose, malt, gelatin, talc, and vegetable oils. Optional active agents may be included in the pharmaceutical composition that do not substantially affect the activity of the compounds of the invention.

[0058] The present application is further described below by way of examples, but the scope of the present application is not limited thereby.

[0059] The main reagent information used in the following examples is shown in Table 1.

[0060] Table 1 List of main reagents

[0061]

[0062] The main instrument information used in the following examples is shown in Table 2.

[0063] Table 2 Instrument information

[0064]

[0065]

[0066] The information of the tested drugs used in the following examples is as follows:

[0067] 1. LF0376

[0068] Provider: Wuxi Lingfang Biopharmaceutical Technology Co., Ltd. Lot: CR-C-210219013-FP22001

[0069] Purity: 98.6%

[0070] Description of properties: Powder Molecular weight: Salt: 835.09; Free base: 738.38 Correction factor: 1.15

[0071] Saved in: RT

[0072] The drug solution was kept at 4°C during administration.

[0073] 2. Ibrutinib

[0074] Provider: MCELot:136640, HY-10997

[0075] Purity: 99.46%

[0076] Correction factor: NA

[0077] Description: Powder

[0078] Store at: 4℃

[0079] The drug solution was kept at 4°C during administration.

[0080] 3. Zanubrutinib

[0081] Provided by: MCE

[0082] Lot:79640,HY-101474A

[0083] Purity: 99.08%

[0084] Correction factor: NA

[0085] Description: Powder

[0086] Store at: 4℃

[0087] The drug solution was kept at 4°C during administration.

[0088] Example 1 In vivo efficacy evaluation of the test drug on PDX tumor transplantation model

[0089] 1. LF0376 combined with Zanubrutinib (ZAN)

[0090] 1.1 Compound preparation

[0091] The LF0376 200mg / kg group was prepared with 5% DMSO + 95% (10% HP-β-CD). The specific preparation method is: weigh 210mg LF0376, add 0.53ml DMSO, and vortex to obtain a clear yellow solution. Then add 9.975ml (10% HP-B-CD) and vortex to obtain a uniform suspension. The suspension was adjusted to pH = 3 to obtain a clear solution. After preparation, it was divided into 5ml EP tubes, 3.3mL per tube, and stored at 4℃. Prepare once every three days.

[0092] Zanubrutinib is prepared with 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% saline. The specific preparation method is: 60mg Zanubrutinib is added to 6ml DMSO to prepare the mother solution, and then divided into 5ml EP tubes at 0.4ml per tube. When using, add 1.6ml PEG300, 0.2ml Tween 80, and 1.8ml saline in sequence, and store at 4℃. Prepare once every three days.

[0093] 1.2 Construction of PDX tumor transplantation model

[0094] 40 female NOG mice were inoculated with patient PDX in the axilla. NOG mice were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. They were 6-7 weeks old at the time of tumor inoculation. Feeding and management conditions: The mice were raised according to SPF animal feeding conditions, and the cages, bedding, feed and drinking water were sterilized by high temperature and high pressure. The cages were placed in the IVC, with 3-5 animals per cage. The indoor temperature of the animal room was 21-25°C, and the relative humidity was 40%-70%. PDX came from patients with diffuse large B-cell lymphoma and belonged to the non-germinal center (non-GCB) subtype. Immunohistochemical results of the PDX model: CD10-, MUM-1 (100%+), Bcl6 (80%+), CD20+, Bcl2+, CD3-, Ki67 (90%+).

[0095] On the 30th day after inoculation, the mice were regrouped according to the tumor volume, with 8 mice in each group, a total of 4 groups, and a total of 32 mice. The mean tumor volume of each group reached 133.47±1.75mm 3 , which is Day 0. The remaining mice were kept at the end of the experiment or when the tumor burden reached 1500 mm 3 The mice in each group were given the drug according to the set dose. The tumor volume was measured every 3 days. Each group was given different doses and drugs, see Table 3 and Figure 1 .

[0096] Table 3 Experimental dosage and grouping

[0097]

[0098] Note: The vehicle control group was given 5% DMSO + 95% (10% HP-β-CD). The vehicle and LF0376 were administered starting at Di 0 (Di: Days of injection), twice a day, with an interval of 8 hours. Zanubrutinib was administered by gavage once a day.

[0099] 1.3 Indicator Observation

[0100] 1.3.1 Tumor volume

[0101] Tumor volume was measured every 3 days. The calculation formula of tumor volume (TV) is: TV = 1 / 2 × a × b 2 Wherein, a and b represent the long diameter and short diameter of the tumor mass, respectively.

[0102] 1.3.2 Weight

[0103] The body weight of the animals was measured every 3 days.

[0104] 1.4 Data Analysis

[0105] All data are expressed as mean ± sem.

[0106] PRISM software was used for statistical analysis, one-way ANOVA was used for data analysis, and Tukey's method was used for comparison among groups.

[0107] 1.5 Experimental Results

[0108] This phase is a study on the combination of LF0376 and Zebutinib, with a total of 27 days of medication.

[0109] like Figure 2 Observation of the overall tumor inhibition curve showed that the LF0376 monotherapy group, the zanubrutinib group, and the LF0376 combined with zanubrutinib group could inhibit tumor growth compared with the control group, among which the tumor inhibition effect of the combination group was the most significant.

[0110] like Figure 3 The tumors were weighed 27 days after administration, and it was found that the tumor weight in the LF0376 combined with Zebutinib group was significantly smaller than that in the control group and the two single-drug groups.

[0111] like Figure 4 During the treatment, the weight of mice in the control group increased significantly, which is consistent with the natural law that the tumor grows larger and the mice become heavier. After medication, the LF0376 monotherapy group, the zanubrutinib group, and the LF0376 combined with zanubrutinib group significantly reduced the tumor volume of mice compared with the control group, thereby reducing the weight of mice, and all did not exceed the range of mouse weight loss, indicating that both combined medication and monotherapy are well tolerated and safe in mice.

[0112] 2. LF0376 combined with ibrutinib (IBR)

[0113] 2.1 Compound preparation

[0114] The LF0376 100mg / kg group was prepared with 5% DMSO + 95% (10% HP-β-CD). The specific preparation method is: weigh 210mg LF0376, add 1.05ml DMSO, and vortex to obtain a clear yellow solution. Then add 19.95ml (10% HP-B-CD) and vortex to obtain a uniform suspension. The suspension was adjusted to pH = 3 to obtain a clear solution. After preparation, it was divided into 5ml EP tubes, 3.3mL per tube, and stored at 4℃. Prepare once every three days.

[0115] Ibrutinib is prepared with 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% saline. The specific preparation method is: 240mg Ibrutinib is added to 6ml DMSO to prepare the mother solution, and then divided into 5ml EP tubes at 0.4ml per tube. When using, add 1.6ml PEG300, 0.2ml Tween 80, and 1.8ml saline in sequence, and store at 4℃. Prepare once every three days.

[0116] 2.2 Construction of PDX tumor transplantation model

[0117] 40 female NOG mice were inoculated with patient PDX in the axilla. NOG mice were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. They were 6-7 weeks old at the time of tumor inoculation. Feeding and management conditions: The mice were raised according to SPF animal feeding conditions, and the cages, bedding, feed and drinking water were sterilized by high temperature and high pressure. The cages were placed in the IVC, with 3-5 animals per cage. The indoor temperature of the animal room was 21-25°C, and the relative humidity was 40%-70%. PDX came from patients with diffuse large B-cell lymphoma and belonged to the non-germinal center (non-GCB) subtype. Immunohistochemical results of the PDX model: CD10-, MUM-1 (100%+), Bcl6 (80%+), CD20+, Bcl2+, CD3-, Ki67 (90%+).

[0118] On the 24th day after inoculation, the mice were regrouped according to tumor volume, with 8 mice in each group, for a total of 4 groups. The mean tumor volume of each group reached 108.72±0.33mm 3 , which is day 0. The remaining mice were kept at the end of the experiment or when the tumor burden reached 1500 mm 3 The mice were then killed. The mice were given the prescribed doses for each group. The tumor volume and body weight were measured every 3 days. Each group was given different doses and drugs, as shown in Table 4 and Figure 5 .

[0119] Table 4 Experimental dosage and grouping

[0120]

[0121] Note: The vehicle control group was given 5% DMSO + 95% (10% HP-β-CD). The vehicle and LF0376 were administered starting at Di 0 (Di: Days of injection), twice a day, with an interval of 8 hours. Ibrutinib was administered by gavage once a day.

[0122] 2.3 Indicator Observation

[0123] Same as 1.3.

[0124] 2.4 Data Analysis

[0125] Same as 1.4.

[0126] 2.5 Experimental Results

[0127] This phase is a study on the combination of LF0376 and ibrutinib, with a total of 27 days of administration.

[0128] like Figure 6 Observation of the overall tumor inhibition curve showed that the LF0376 monotherapy group, the ibrutinib group, and the LF0376 combined with ibrutinib group could inhibit tumor growth compared with the control group, among which the combined group had the most significant tumor inhibition effect.

[0129] like Figure 7 The tumors were weighed 27 days after administration, and it was found that the tumor weight in the LF0376 combined with ibrutinib group was significantly smaller than that in the control group and the two single-drug groups.

[0130] like Figure 8 During the treatment, the weight of mice in the control group increased significantly, which is consistent with the natural law that the tumor grows larger and the mice become heavier. After medication, the LF0376 monotherapy group, the ibrutinib group, and the LF0376 combined with ibrutinib group significantly reduced the tumor volume of mice compared with the control group, thereby reducing the weight of mice, and all did not exceed the range of mouse weight loss, indicating that both combined medication and monotherapy are well tolerated and safe in mice.

[0131] Example 2 In vivo efficacy evaluation of the test drug on the human DLBCL xenograft tumor model LD1-0026-361717

[0132] This example mainly tests the growth inhibitory effect or complete cure ability of the test drugs LF0376 alone, Ibrutinib alone, Zanubrutinib alone, and LF0376 combined with Ibrutinib or Zanubrutinib on the human DLBCL in vivo transplanted tumor model LD1-0026-361717.

[0133] 1. Compound preparation

[0134] See Table 5 for details:

[0135] Table 5 Preparation of test drugs

[0136]

[0137] 2. In vivo transplanted tumor model

[0138] LD1-0026-361717 human DLBCL tumor tissue, passed to FP3+2 generation, was used for this efficacy experiment.

[0139] For basic information of the LD1-0026-361717PDX model, please see Table 6.

[0140] Table 6 Basic information of the model

[0141]

[0142] 95 NU / NU mice, female, weighing 18-21 g, were purchased from Beijing Weitonglihua Laboratory Animal Technology Co., Ltd. (SCXK (Beijing) 2021-0006), with a certificate number of 110011231108918138. Laboratory animal use license number: SYXK (Shaanxi) 2023-008. Breeding environment: SPF grade. The animals were adapted for observation for 3 days before the start of the experiment.

[0143] The tumor mass of the FP3+1 generation LD1-0026-361717 human DLBCL in vivo transplanted tumor was cut into tumor tissues of approximately 3mm×3mm×3mm (approximately 45-60mg) and inoculated subcutaneously into NU / NU mice. The mice were observed after inoculation and the growth of the tumor was monitored. On the 28th day of inoculation, the average tumor volume of the tumor-bearing mice was 137.11±6.36mm 3 The grouping and dosing were performed at the same time, and the day of grouping and dosing was defined as day 0. The specific grouping information and dosing regimen are shown in Table 7.

[0144] Table 7 Drug administration and treatment

[0145]

[0146] Note: Dosing volume: adjust the dosing volume according to the weight of tumor-bearing mice (0.2mL / 20g); PO: intragastric administration; QD: once a day; BID: twice a day, with an interval of about 8 hours.

[0147] 3. Indicator observation

[0148] 3.1 Tumor volume

[0149] Tumor volume was measured twice a week using a vernier caliper and calculated using the formula V = 0.5a × b 2 , a and b represent the long diameter and wide diameter of the tumor, respectively.

[0150] 3.2 Relative tumor proliferation rate T / C (%)

[0151] The calculation formula is as follows: T / C% = T RTV / C RTV ×100%(T RTV :RTV in treatment group; C RTV : RTV of Vehicle group). The relative tumor volume (RTV) was calculated based on the results of tumor measurement. The calculation formula is RTV=V t / V 0 , where V 0 When the drug is administered in groups (i.e., d 0 ) The average tumor volume measured, V t is the average tumor volume at a certain measurement, T RTV With C RTV Get data from the same day.

[0152] 3.3 Tumor growth inhibition rate TGI (%)

[0153] TGI (%) = [1-(T i -T 0 ) / (V i -V 0 )]×100%, T i is the average tumor volume of the compound group after the start of administration, T 0 is the average tumor volume of the compound group at the first administration, V 0 is the average tumor volume of the Vehicle group at the first administration, V i The average tumor volume of the Vehicle group after the start of drug administration. If TGI (%)>50%, it is considered that the compound has a significant effect of inhibiting tumor growth.

[0154] 3.4 weight

[0155] The weight of the mice was measured every day. At the same time, the relative change ratio of the body weight of the mice after administration was calculated: RCBW (%) = (BW i –BW 0 ) / BW 0 ×100, BW i BW is the body weight after the start of drug administration. 0 The body weight at the time of first administration.

[0156] 4. Data Analysis

[0157] All data are expressed as Mean±SEM, SEM=SD / SQRT(n), n=number of animals in the experimental group.

[0158] 5. Experimental results

[0159] like Fig. 9 , Fig.10 , Fig.11 As shown in Table 8, on day 28, the average tumor volume in the Vehicle group was 1470.55±411.29mm 3 The average tumor volumes of the LF0376 monotherapy group, Ibrutinib monotherapy group, Zanubrutinib monotherapy group, LF0376+Ibrutinib group, and LF0376+Zanubrutinib group were 1219.51±254.70mm 3 、906.95±185.57mm 3 、972.72±342.44mm 3 、566.26±159.12mm 3 and 752.64±212.66mm 3 ; TGI (%) were 18.60%, 42.24%, 37.33%, 67.86% and 53.86% respectively; T / C (%) were 84.86%, 61.94%, 66.29%, 38.45% and 51.21% respectively; LF0376+Ibrutinib group and LF0376+Zanubrutinib group showed significant inhibitory effect on tumor growth in human DLBCL PDX model LD1-0026-361717 compared with Vehicle group. LF0376+Ibrutinib group and LF0376+Zanubrutinib group showed stronger inhibitory effect on tumor growth compared with LF0376 monotherapy group and Ibrutinib / Zanubrutinib monotherapy group, indicating that LF0376 can enhance the anti-tumor effect of Ibrutinib or Zanubrutinib.

[0160] Table 8 Summary of the anti-tumor efficacy evaluation of the tested drugs in the LD1-0026-361717 human DLBCL subcutaneous xenograft tumor model

[0161]

[0162] like Fig.12 , Fig.13 , Fig.14As shown in Table 8, on the 28th day, the average tumor weights of the Vehicle group, LF0376 monotherapy group, Ibrutinib monotherapy group, Zanubrutinib monotherapy group, LF0376+Ibrutinib group, and LF0376+Zanubrutinib group were 1.239±0.375 g, 1.024±0.218 g, 0.739±0.162 g, 0.785±0.297 g, 0.475±0.134 g, and 0.596±0.184 g, respectively, and the tumor weight results were basically consistent with the tumor volume results.

[0163] like Fig.15 , Fig.16 As shown in Table 9, on day 28, the RCBW (%) of the Vehicle group, LF0376 monotherapy group, Ibrutinib monotherapy group, Zanubrutinib monotherapy group, LF0376+Ibrutinib group and LF0376+Zanubrutinib group were 11.91±2.20%, 12.00±1.28%, 5.48±1.16%, 9.32±1.80%, 4.82±1.64% and 5.33±1.33%, respectively.

[0164] Table 9 RCBW (%) of animals treated with the test drugs in the LD1-0026-361717 human DLBCL subcutaneous xenograft tumor model

[0165]

[0166]

[0167] 6. Experimental conclusion

[0168] LF0376 alone, Ibrutinib alone, and Zanubrutinib alone did not show significant anti-tumor effects in this model at the current dose level; LF0376 combined with Ibrutinib and LF0376 combined with Zanubrutinib showed significant anti-tumor effects in this model, indicating that LF0376 can significantly enhance the anti-tumor effects of Ibrutinib and Zanubrutinib. During the treatment with the test drug, no animals in each group showed significant weight loss, indicating that the test drug was safe.

[0169] Example 3 Evaluation of the efficacy of the test drug in the Balb / c mouse A20 tumor model

[0170] The purpose of this example is to evaluate the efficacy and mechanism of the test drug in the Balb / c mouse A20 tumor model (mouse B cell lymphoma).

[0171] 1. Compound preparation

[0172] See Table 10 for details

[0173] Table 10 Preparation of test drugs

[0174]

[0175] Note: *Dosage concentration is based on active ingredient.

[0176] 2. Animal Model

[0177] Animal information is shown in Table 11:

[0178] Table 11 Experimental Animal Information

[0179]

[0180] The animals were isolated and adaptively raised before experimental treatment.

[0181] A20 cells were cultured and expanded in vitro, and cells in the logarithmic growth phase were collected and resuspended in PBS. The cell suspension concentration was 5×10 6 / mL.

[0182] Use a 1 mL syringe to inject the cell suspension into the right subcutaneous part of Balb / c mice. Each animal is injected with 100 μL of the suspension. The number of cells inoculated is 5 × 10 5 / Only.

[0183] The average tumor volume was 60.75±0.48mm 3 When the tumor was collected, animals with large or small tumors or irregular tumor shapes were eliminated, and the animals were divided into 6 groups with 6 animals in each group by random block method. The day of grouping was defined as PG-D0.

[0184] Drug administration was started according to the grouping scheme. Each group was administered by gavage. The administration volume of each group was 5 mL / kg. The administration frequency was once or twice a day. During the experiment, the animal body weight was weighed and the tumor volume was measured three times a week.

[0185] The experimental endpoint was PG-D13, all mice were euthanized, tumor tissues were removed, weighed and photographed. Based on the tumor volume and body weight measured at PG-D12, the tumor volume inhibition rate (TGI) and animal body weight change rate (BWC%) were calculated respectively.

[0186] The dosing regimen for mice is shown in Table 12:

[0187] Table 12 Dosage schedule for each group of mice

[0188]

[0189] Note: G: Group; po: intragastric administration;

[0190] 1. The day of grouping was defined as PG-D0, and drug administration began on PG-D0;

[0191] 2. Dosing volume: adjusted according to the weight of the mouse;

[0192] 3. After the experiment, the mice will be processed according to customer needs.

[0193] Animal grouping and identification:

[0194] When the average tumor volume reached approximately 60.75 ± 0.48 mm 3 At , mice were randomly divided into 6 groups according to tumor volume, with 6 mice in each group. Detailed information is shown in Table 13 below: The cages were clearly marked with cage cards, including animal number, sex, strain, date of receipt, treatment, study number, and group number.

[0195] Table 13 Experimental Animal Grouping Information

[0196]

[0197] 3. Indicator observation

[0198] 3.1 Tumor volume (TV)

[0199] TV=1 / 2×a×b 2

[0200] Wherein: a represents the long diameter of the tumor; b represents the short diameter of the tumor.

[0201] 3.2 Tumor volume inhibition rate (TGI)

[0202] TGI=[1-(TV D t Treatment group-TV D 0 Treatment group) / (TV D t Control group-TV D 0 Control group)]×100%

[0203] TV D t Experimental group: tumor volume of the treatment group on day t after drug administration

[0204] TV D 0 Experimental group: tumor volume of the treatment group at the time of group administration

[0205] TV D t Control group: tumor volume of the control group on day t after administration

[0206] TV D 0 Control group: The tumor volume of the control group at the time of group drug administration.

[0207] 3.3 Animal body weight change rate (BWC%)

[0208] Weight change rate = (BW D t -BW D 0 ) / BW D 0 ×100%

[0209] BW D t : Animal body weight on day t after administration

[0210] BW D 0 : Animal body weight when grouped and dosed.

[0211] 3.4 Tumor weight inhibition rate (IR)

[0212] IR=(W C -W T ) / W C ×100%

[0213] Among them, W C W represents the tumor weight of the control group; T Indicates tumor weight in treatment group.

[0214] 4. Data Analysis

[0215] 5.1 Mouse tumor volume

[0216] like Fig.17 , Fig.18 As shown in Tables 14 and 15, the average tumor volume of the control group was 687.68±46.59mm 3 The average tumor volumes of the LF0376 monotherapy group, Ibrutinib monotherapy group, Zanubrutinib monotherapy group, LF0376+Ibrutinib group, and LF0376+Zanubrutinib group were 551.12±40.66mm, respectively. 3 、640.57±48.47mm 3 、651.25±39.04mm 3 、497.63±57.96mm 3 and 454.45±46.55mm 3, TGI were 21.74%, 7.47%, 5.79%, 30.30% and 37.12% respectively. LF0376+Ibrutinib group and LF0376+Zanubrutinib group showed significant inhibition of tumor growth compared with the control group. LF0376+Ibrutinib group and LF0376+Zanubrutinib group showed more significant tumor inhibition effect compared with LF0376 monotherapy group and Ibrutinib / Zanubrutinib monotherapy group, respectively.

[0217] Table 14 Average tumor volume (mm) of mice in each group during treatment 3 )

[0218]

[0219] Note: Data are expressed as Mean ± SEM.

[0220] Table 15 TGI of mice in each experimental group of PG-D12 (%)

[0221]

[0222] 5.2 Tumor weight in mice

[0223] like Fig.19 As shown in Table 16, for PG-D13, the average tumor weight of the control group was 1.8387±0.2200 g, and the average tumor weights of the LF0376 monotherapy group, the Ibrutinib monotherapy group, the Zanubrutinib monotherapy group, the LF0376+Ibrutinib group, and the LF0376+Zanubrutinib group were 1.1853±0.1562 g, 1.5809±0.1216 g, 1.4855±0.1700 g, 1.3331±0.1810 g, and 1.0855±0.1081 g, respectively, and the IRs were 35.54%, 14.02%, 19.21%, 27.50%, and 40.96%, respectively. The tumor weight results were basically consistent with the tumor volume results.

[0224] Table 16 Average tumor weight of mice in each group of PG-D13 (g)

[0225]

[0226] Note: n / n means: actual number of samples / original number of samples.

[0227] 5.3 Mouse body weight

[0228] like Fig. 20As shown in Table 17, the average body weights of PG-D12, Group 1, Group 2, Group 3, Group 4, Group 5 and Group 6 mice were 25.97±1.13 g, 24.73±0.89 g, 26.33±1.20 g, 25.68±0.69 g, 24.52±1.06 g and 24.80±0.32 g, respectively.

[0229] like Fig.21 As shown in Table 18, the average weight of mice in Group 1, Group 2, Group 3, Group 4, Group 5 and Group 6 increased with PG-D12, and the weight change rates were 9.6±1.4%, 5.3±1.4%, 9.6±2.5%, 7.9±3.0%, 5.2±2.8% and 5.8±1.8%, respectively. The weight change rates of mice in the experimental groups during the treatment period ranged from -10.8% to 21.6%. No mice were suspended from the drug due to significant weight loss or poor condition.

[0230] Table 17 Average body weight of mice in each group during treatment (g)

[0231]

[0232]

[0233] Note: Data are expressed as Mean ± SEM.

[0234] Table 18 Weight change rate of mice in each group during treatment compared with the baseline (%)

[0235]

[0236] Note: The body weight change rate was calculated based on the body weight on PG-D0. Data are expressed as Mean ± SEM.

[0237] 6. Experimental conclusion

[0238] The safety of the test drug was good during the treatment. LF0376 alone had a certain anti-tumor effect on A20, and the combined anti-tumor effect of LF0376+Ibrutinib and LF0376+Zanubrutinib was more significant, indicating that LF0376 can significantly enhance the anti-tumor effect of Ibrutinib and Zanubrutinib.

[0239] The above embodiments are merely illustrative of the principles and effects of the present invention, and are not intended to limit the present application. Anyone familiar with the technology may modify or change the above embodiments without violating the spirit and scope of the present application. Therefore, all equivalent modifications or changes made by a person of ordinary skill in the art without departing from the spirit and technical ideas disclosed by the present invention shall still be covered by the claims of the present application.

Claims

1. Use of CCR2 / 5 dual receptor antagonists in the preparation of drugs for treating or preventing B-cell lymphoma.

2. The use according to claim 1, characterized in that The CCR2 / 5 dual receptor antagonist is selected from a combination of one or more of LF0376, BMS-813160, and Cenicriviroc; preferably, the CCR2 / 5 dual receptor antagonist is selected from LF0376.

3. A pharmaceutical composition, characterized in that The invention comprises a CCR2 / 5 dual receptor antagonist for use as claimed in any one of claims 1 to 2, and a Bruton's tyrosine kinase inhibitor.

4. The pharmaceutical composition according to claim 3, characterized in that The Bruton's tyrosine kinase inhibitor is selected from zanubrutinib, ibrutinib, spebrutinib, acalabrutinib, olmutinib, poseltinib, tirabrutinib, evobrutinib, fenebrutinib, vecabrutinib, ARQ-531, BMS-986195, BMS-986142, CGI-1746, GDC-0834, RN-486, JNJ-64264681, DTR A combination of one or more of MWXHS-12, CT-1530, AC0058TA, ICP-022, WXFL10230486, SHR1459, PRN-1008, PRN-473, PRN-2246, LOU-064, LOXO-305, ABBV-105, PCI-45292, TAK-020, M-7583, BIIB-068, BMS-935177, CNX-774, TAS-5315, TGH-663, and LFM-A13.

5. The pharmaceutical composition according to claim 4, characterized in that The Bruton's tyrosine kinase inhibitor is selected from zanubrutinib or ibrutinib.

6. The pharmaceutical composition according to claim 5, characterized in that The pharmaceutical composition includes LF0376 and ibrutinib; Preferably, the weight ratio of LF0376 to ibrutinib is 0.5-10:

1.

7. The pharmaceutical composition according to claim 5, characterized in that The pharmaceutical composition includes LF0376 and zanubrutinib; Preferably, the weight ratio of LF0376 to zanubrutinib is 0.8-40:

1.

8. Use of the pharmaceutical composition according to any one of claims 3 to 7 in the preparation of a drug for treating or preventing cancer, wherein the cancer is selected from one or more combinations of B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, slow-cell lymphoma, bladder cancer, blood cancer, bone cancer, brain cancer, breast cancer, central nervous system cancer, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, gallbladder cancer, gastrointestinal cancer, external genital cancer, urogenital tract cancer, head cancer, kidney cancer, laryngeal cancer, liver cancer, lung cancer, muscle tissue cancer, cervical cancer, oral or nasal mucosal cancer, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, spleen cancer, small intestine cancer, large intestine cancer, stomach cancer, testicular cancer and thyroid cancer.

9. The use according to claim 8, characterized in that The B cell lymphoma is diffuse large B cell lymphoma.

10. A drug for treating cancer, comprising the CCR2 / 5 dual receptor antagonist for use as claimed in any one of claims 1 to 2, or the pharmaceutical composition as claimed in any one of claims 3 to 7, and pharmaceutically acceptable excipients and / or carriers.

Citation Information

Patent Citations

  • Pharmaceutical composition containing ibrutinib and application thereof

    CN111110685A

  • Combination of enzastaurin and inhibitors of BTK and uses thereof

    CN112512527A

  • Application of HDAC (histone deacetylase) inhibitor and ibrutinib in preparation of medicine for preventing or treating mantle cell lymphoma

    CN115554301A

  • Pharmaceutical combinations for treating cancer

    WO2023285677A1